HIVID
LOE ApproachingNDAORALTABLETPriority Review
Approved
Jun 1992
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
2
Data completeness
2/8 — Basic
Priority Review
Drug data last refreshed 2d ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
HIVID is an oral small-molecule antiretroviral approved in 1992 for HIV treatment. The generic name and mechanism of action are not disclosed in available data. It represents an early-generation HIV therapy from the nucleoside reverse transcriptase inhibitor (NRTI) class era.
LOE Approaching
With LOE approaching and zero linked job openings, this legacy HIV product faces declining commercial demand and minimal team expansion opportunities.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (2)
The Safety and Effectiveness of Retrovir Plus HIVID Combined With Either Nevirapine or Invirase in the Treatment of HIV Infection
225 enrolled
HIV Infections
A Randomized, Open-Label Study of Alternative Treatment Combinations of Dideoxycytidine (HIVID; ddC) and Zidovudine (AZT) in Patients With HIV Infection
528 enrolled
HIV Infections
Career Relevance
With zero linked job openings and approaching loss of exclusivity, HIVID offers minimal career growth or advancement potential. Roles on this product are typically in wind-down or transition management rather than growth-oriented positions.
Brand Manager (legacy product)
Worked on HIVID at Roche? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.